Company Overview

Titan Pharmaceuticals, Inc. is a biopharmaceutical company with valuable assets in the CNS (central nervous system) area. On May 6, 2009, US Food & Drug Administration granted marketing approval to Fanapt™ (iloperidone) for the treatment of adult patients with schizophrenia. This milestone represents the first marketing approval for a product out-licensed by Titan. The global sales from atypical antipsychotics, the same class of drugs like Fanapt™, exceeded $20 billion in 2007. Titan is entitled to receive 8-10% of global annual sales as royalty revenue, which may commence as early as the end of 2009. Titan is also focused on adding value to the company from its other assets, particularly Probuphine which is in phase 3 clinical development. Additional information on the Probuphine program is available in the PRODUCTS section of this website. If you are interested in any of Titan's current products, please contact Sunil Bhonsle, President, at: sbhonsle@titanpharm.com